ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
生物醫藥B類股
496.720
-5.792
-1.15%
手動刷新
漲家數:
6
跌家數:
25
平家數:
2
市盈率:
- -
高:
507.303
開:
502.573
低:
495.158
收:
502.512
成交量:
8,175.03萬
成交額:
18.06億
市值:
3,152.73億
流通市值:
2,806.09億
資料載入中...
總覽
新聞資訊
創新藥企密集進入臨床數據驗證期,石藥集團升逾4%!華寶基金港股通創新藥ETF(520880)再收半年線!
新浪基金
·
09/03
港股開盤向好 恒指高開0.68% 信達生物(01801)漲3.73%
金吾财讯
·
09/03
港股異動 | 康方生物(09926.HK)高開近4% 依沃西迭代K藥 HARMONi-2取得OS陽性結果
智通财经
·
09/03
康方生物(09926)出現大手賣出19.2萬股,成交價$91.0,涉資1.747千萬
阿斯达克财经
·
09/03
【灣區早參】深圳啓動私募合規自查;8月廣州二手住宅市場網籤量按年微增
金吾财讯
·
09/03
康方生物:依沃西NSCLC一線治療HARMONi-2研究OS期中分析達關鍵次要終點
南方财经网
·
09/03
首個國產IL-17A/F雙靶點抑制劑獲批,這一40年來「有研究無產品」的靶點迎臨床突破|掘金創新藥
每日经济新闻
·
09/02
康寧傑瑞製藥-B(09966.HK)9月2日耗資98.58萬港元回購11.5萬股
智通财经
·
09/02
美股異動 | 再鼎醫藥漲逾7%,DLL3 ADC啓動一線SCLC全球三期臨床
智通财经
·
09/02
國家醫保局:不要將病種支付標準與醫務人員績效工資掛鈎;2連板小方製藥披露股價異動公告丨醫藥早參
每日经济新闻
·
09/02
和鉑醫藥:披露戎一平辭任具體緣由
GPLP
·
09/02
康諾亞-B(02162)就司普奇拜單抗注射液東南亞和中亞等18個國家和地區上市註冊和商業化達成許可協議
智通财经
·
09/02
創新藥半年報冰火兩重天:百濟神州一款藥賣了161億元、六成藥企還在求生 ,「賣藥」仍是終極命題
每日经济新闻
·
09/02
康希諾生物上半年海外收入按年增長4724.19% 體系化「出海」打開增長空間
证券日报网
·
09/02
歐康維視生物-B(01477):OT-211 III期臨床試驗完成患者入組
智通财经
·
09/02
榮昌生物(09995):截至8月末累計回購4.1萬股A股
智通财经
·
09/02
海西新藥:已提交自研創新藥HX9428臨床試驗申請
财中社
·
09/02
執行董事王玉曉減持榮昌生物(09995)1.35萬股 每股作價約81.54港元
智通财经
·
09/02
深入挖掘創新項目 深圳市市場監督管理局組織開展2026年醫療器械重點創新項目路演遴選活動
深圳新闻网
·
09/02
東方證券股份有限公司(DFZQ)減持康諾亞-B(02162.HK)4.8萬股 每股作價78.401港元
智通财经
·
09/02
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BK1574/news?page=16"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":496.71994,"timestamp":1789459707407,"preClose":502.51205,"halted":0,"volume":81750325,"delay":0,"changeRate":-0.011526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-5.792114,"latestTime":"09-15 16:00:00","open":502.57327,"high":507.303,"low":495.15784,"amount":1806018702,"amplitude":0.024169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":3.744174,"peRate":166.585651,"turnoverRate":0.00304,"increases":7,"decrements":24,"flats":1,"marketCap":315273116400,"floatMarketCap":280608949080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":507.303,"amplitude":0.024169,"preClose":502.51205,"low":495.15784,"pbRate":"3.744174","latestPrice":496.71994,"volume":81750325,"delay":0,"open":502.57327,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":518.573,"twentyDayClose":502.603,"sixtyDayClose":431.958,"secType":"PLATE","market":"HK","turnoverRate":0.00304,"peRate":166.585651,"marketCap":315273116400,"floatMarketCap":280608949080,"timestamp":1789459707407,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:16,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664231028","title":"創新藥企密集進入臨床數據驗證期,石藥集團升逾4%!華寶基金港股通創新藥ETF(520880)再收半年線!","url":"https://stock-news.laohu8.com/highlight/detail?id=2664231028","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664231028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 10:52","pubTimestamp":1788403920,"startTime":"0","endTime":"0","summary":"9月3日,港股创新药链继续活跃,创新药龙头公司领涨,石药集团、中国生物制药双双涨超4%。纯正创新药指数——恒生港股通创新药精选指数一度冲高逾2%,跟踪该指数的港股通创新药ETF华宝盘中再收半年线。中金公司提示,创新药较多公司进入临床数据验证阶段,值得自下而上关注。据统计,港股通创新药ETF华宝覆盖的48家创新药研发公司中,31家上半年实现盈利,归母净利同比正增长的有33家,占比近7成。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-03/doc-iniqpkry1034045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1226288170.HKD","LU1226287529.USD","LU1328277881.USD","BK1521","BK1515","LU0326950275.SGD","LU0315179316.USD","LU1226288253.USD","IE00BZ08YT58.USD","LU1951186391.HKD","KURE","LNGR","MEDX","IE0008368742.USD","LU1226287875.USD","LU0880133367.SGD","LU0501845795.SGD","520880","BK1191","LU0067412154.USD","IE00B031HY20.USD","HK0000165453.HKD","IBBQ","159992","IE00B5MMRT66.SGD","FLHK","IE00BZ08YR35.GBP","LU2039709279.SGD","LU0314109678.HKD","LU1960683339.HKD","LU1152091168.USD","LU0072913022.USD","01093","IE0008369823.USD","06978","LU1008478684.HKD","LU1152091754.HKD","LU0140636845.USD","LU1226287792.SGD","BK1574","LU1807302812.USD","BK1161","IE00BZ08YS42.EUR","IE00B543WZ88.USD","SG9999004220.SGD","159316","LU1813983027.USD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664840055","title":"港股開盤向好 恒指高開0.68% 信達生物(01801)漲3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664840055","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664840055?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 09:26","pubTimestamp":1788398766,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好,恒指高开0.68%,国企指数高开0.75%,恒生科技指数高开0.71%。信达生物涨3.73%,联想集团涨3.33%,老铺黄金涨2.60%,京东健康涨2.43%,农夫山泉涨2.39%,网易涨1.82%。京东健康高开2.43%,公司与立康生命科技签署战略合作协议。外围气氛持续紧张,投资者忧虑债息高企及地缘政局紧张,不过考虑到早前跌势较大,短线大市有机会展现技术反弹,预料指数继续于25,000至26,000点水平上落。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGVhNjVkZTQ2ODU4ZWQyYjc4YjcyMmRkNWUzMjAzNTczNzI1NTIy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGVhNjVkZTQ2ODU4ZWQyYjc4YjcyMmRkNWUzMjAzNTczNzI1NTIy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990504","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683595622.HKD","LU0052756011.USD","SOCL","LU0572944931.SGD","HK0000306685.HKD","SG9999001093.SGD","LU0320764755.SGD","LU0972618739.USD","LU0737861772.HKD","LU2257852520.SGD","IE0003795394.USD","BK1544","LU1224709979.USD","BK1180","BK1609","LU0117844026.USD","LU0877626530.USD","KURE","BK1588","LU0327786744.USD","LU0348827113.USD","LU0650527681.SGD","LU1211504680.USD","BK1610","LU2048586759.USD","LU1226288097.SGD","LU2152927971.USD","LU0106252389.USD","BK1170","LU1282651121.HKD","LU1675838814.USD","LU0072462343.USD","IE00B0JY6N72.USD","LU0737861699.HKD","LU0329678170.USD","LU1831875114.USD","LU1813983027.USD","BK1571","09115","09999","BNGE","LU0594300419.USD","IE00B5MMRT66.SGD","LU0865486749.SGD","LU2293587155.HKD","LU0328353924.USD","00857","LNVGY","LU0862451753.SGD","LU0029875118.USD","LU1655091459.SGD","BK1578","LU0640798160.USD","LU2097828474.EUR","LU0164865239.USD","LU0791590937.USD","06181","BK1531","SG9999006597.SGD","IE00B031J352.USD","LU0244354667.USD","LU0315178854.USD","LU0831103253.SGD","IE00B067MR52.USD","LU0106959298.USD","03419","81024","IE0032834883.USD","IE0034224299.USD","LU0181495838.USD","LU2242644610.SGD","LU1969619763.USD","86618","BK1142","LU0164880469.USD","BK1193","LU0210526637.USD","LU0543330483.HKD","FDNI","LU1226287875.USD","BK1226","LU0314109678.HKD","LU2039709279.SGD","LU0890818403.SGD","NNFSF","BK1607","LU1720050803.USD","LU0456846285.SGD","BK1589","LU0149721374.USD","07200","LU1023057109.AUD","LU1734074674.USD","LU2476274720.SGD","IE00BZ08YS42.EUR","LU1497733557.USD","LU1188198961.HKD","LU0205439572.USD","LU2488822045.USD","LU1282651048.USD","601857","LU1119993845.HKD","09926","LU1794554557.SGD","LU0228659784.USD","LU2778985437.USD","BK1214","LU1634259557.SGD","LU2476274308.USD","IE0003895053.USD","HK0000320223.HKD","LU2279701549.SGD","LU0441854154.USD","LU1328277881.USD","83115","LU0821914370.USD","LU0456827905.SGD","IE0031814852.USD","LU0039217434.USD","DRGN","02565","LU0128522157.USD","LU0405327148.USD","LU0417516738.SGD","LU0862451837.USD","LU1785774172.SGD","IE0008368742.USD","IE00B97KM107.HKD","SG9999001051.SGD","LU1235295612.USD","IE00BWDBJ730.SGD","LU0140636845.USD","LU2097828805.USD","BK1200","03037","LU0572940350.SGD","LU1497733631.SGD","LU0287142896.SGD","LU0348766576.USD","02833","LU0417516571.SGD","LU0431992006.USD","MCHmain","LU1880383440.USD","LU0868486357.SGD","BK1608","LU0173614495.USD","SGXZ62798434.SGD","IE0032431581.USD","LU0540923850.HKD","LU2097828557.USD","LU0348784397.USD","SGXZ86797644.SGD","LU2097828631.EUR","BK1590","LU1769817179.HKD","LU1115378108.SGD","LU0326950275.SGD","LU1807302812.USD","LU0672654166.SGD","LU0359202008.SGD","IE00BQJZWZ67.USD","BK1104","LU1497734951.SGD","80992","SG9999003461.SGD","LU0784639295.USD","BK1227","LU0307460666.USD","CRHKY","LU0348805143.USD","600690","LU0588545490.SGD","01024","02800","IE00BZ08YT58.USD","LU0348735423.USD","LU0231483743.USD","00992","LU0588546209.SGD","BK1510","LU1981816686.USD","HK0000320264.USD","KWEB","BK1528","LU0048580855.USD","LU0594300179.USD","00291","LU0607220059.USD","80291","LU1366334578.USD","BK1095","BK1521","LU1226287792.SGD","BK1574","BK1247","LU1251922891.USD","LU0052750758.USD","LU2097828714.EUR","BK1504","LU0359201885.HKD","LU0169518387.USD","LU0572939691.SGD","LU0823413587.USD","LU0633140727.USD","LU0049853897.USD","LU0348825331.USD","LU0348767384.USD","LU2051468812.USD","IE0009570106.USD","LU0531971595.HKD","LU1688375341.USD","LU1522347837.USD","LU0828237510.HKD","LU0310800965.SGD","HK0000306701.USD","IE0008369823.USD","513600","SG9999006514.SGD","LU0348783233.USD","LU1366334651.USD","LU1951186391.HKD","LU1808992512.USD","LU0588545730.USD","LU0210527791.USD","LU0320764599.SGD","LU0588545904.SGD","06690","LU1224444064.USD","LU1634259391.SGD","BK1591","LU0117841782.USD","LU0469268626.HKD","LU0149534421.HKD","SG9999004220.SGD","LU2328871848.SGD","IE00B543WZ88.USD","LU0370786039.SGD","LU0293314216.USD","82800","LU1226288253.USD","03115","LU0264606111.USD","LU1048588211.SGD","LU0593848301.USD","LU1267930227.SGD","06618","LU0675040207.SGD","BK1161","SG9999014674.SGD","LU0348783662.USD","LU1961090484.USD","LU0791591158.USD","IE00BZ08YR35.GBP","LU0502904849.HKD","02382","LU0051755006.USD","SGXZ90724238.SGD","LU1481107354.HKD","IE0003851619.USD","BK1604","LU1303224171.USD","LU0405327494.USD","LU1719994722.HKD","LU0823413660.USD","HSI","IE00B0169L03.USD","IE00BPRC5H50.USD","IE00BYV24P56.USD","LU1328615791.USD","LU0211977185.USD","LU0329678337.USD","LU0634319403.HKD","LU0417516902.SGD","LU1046422090.SGD","LU1226287529.USD","LU1769817096.USD","LU0561508036.HKD","LU0611395673.USD","LU0192582467.USD","LU0633140560.USD","BK1575","LU0605514214.HKD","LU0072913022.USD","IE00B29SXG58.USD","SG9999001846.SGD","BK1515","07500","HK0000165453.HKD","BK1615","07300","TCHI","BK1526","HHImain","IE00B19Z5X02.USD","KSTmain","IE00B031HY20.USD","LU1655091616.SGD","LU0188438112.USD","LU0359201612.USD","LU0463099449.HKD","BK1570","LU0501845795.SGD","HSTECH","NTES","BK1583","LU0128525689.USD","LU0455707207.USD","LU1226288170.HKD","LU0049112450.USD","LU0871576103.HKD","LU1770034418.SGD","09633","LU0708995583.HKD","IE00BMCWC346.EUR","BK1557","LU1880383366.USD","LU2399975544.HKD","LU0898667661.SGD","LU1048596156.SGD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664400398","title":"港股異動 | 康方生物(09926.HK)高開近4% 依沃西迭代K藥 HARMONi-2取得OS陽性結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2664400398","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664400398?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 09:24","pubTimestamp":1788398685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09926","IE00B543WZ88.USD","LU0634319403.HKD","BK1574","BK1161","LU2476274720.SGD","LU0348825331.USD","LU1961090484.USD","LU0417516738.SGD","LU0348766576.USD","LU0348783233.USD","LU2778985437.USD","LU0540923850.HKD","KURE","LU0561508036.HKD","LU0348827113.USD","LU1720050803.USD","LU2488822045.USD","LU2476274308.USD","LU0417516902.SGD","LU2399975544.HKD","IE00B5MMRT66.SGD","LU0348784397.USD","LU1794554557.SGD","LU0348735423.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664812828","title":"康方生物(09926)出現大手賣出19.2萬股,成交價$91.0,涉資1.747千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2664812828","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664812828?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 09:20","pubTimestamp":1788398400,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午09:20出现大手卖出,成交量为19.2万,成交价为港币$91.0,涉资1.747千万。至目前为止,股价升3.645%,今日最高价为$91.0,而最低价为$91.0,总成交量为32.5万股,总成交金额港币$2.913千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26090372/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26090372/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0348766576.USD","IE00B5MMRT66.SGD","LU0417516902.SGD","BK1161","LU0348767384.USD","LU0634319403.HKD","KURE","LU2399975544.HKD","LU2488822045.USD","LU0348827113.USD","LU0417516571.SGD","LU0348784397.USD","LU0348735423.USD","09926","BK1574","LU2476274720.SGD","LU2778985437.USD","LU1794554557.SGD","LU2476274308.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU0417516738.SGD","LU0348825331.USD","LU1961090484.USD","IE00B543WZ88.USD","LU0561508036.HKD","LU0540923850.HKD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664847227","title":"【灣區早參】深圳啓動私募合規自查;8月廣州二手住宅市場網籤量按年微增","url":"https://stock-news.laohu8.com/highlight/detail?id=2664847227","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664847227?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 08:42","pubTimestamp":1788396159,"startTime":"0","endTime":"0","summary":"3、深圳启动私募合规自查深圳证监局近日下发通知,启动2026年深圳辖区私募投资基金合规自查工作。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","IE00B543WZ88.USD","BK4211","BK1574","LU0634319403.HKD","BK1161","LU2476274720.SGD","BK4080","BK4195","LU0348825331.USD","ADC","LU1961090484.USD","BK1589","LU0417516738.SGD","NETL","LU0348766576.USD","LU0348783233.USD","LU2778985437.USD","BK1227","BK1163","KURE","LU0540923850.HKD","LU0561508036.HKD","BK4231","BK1583","IPOS","LU0348827113.USD","LU1720050803.USD","PFS","LU2488822045.USD","LU2476274308.USD","LU0417516902.SGD","LU2399975544.HKD","00933","IE00B5MMRT66.SGD","LU0348784397.USD","LU1794554557.SGD","BK1191","LU0348735423.USD","IE00BPRC5H50.USD","03310","LU0417516571.SGD","LU0348767384.USD","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664842512","title":"康方生物:依沃西NSCLC一線治療HARMONi-2研究OS期中分析達關鍵次要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2664842512","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664842512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 07:12","pubTimestamp":1788390720,"startTime":"0","endTime":"0","summary":"【康方生物:依沃西NSCLC一线治疗HARMONi-2研究OS期中分析达关键次要终点】康方生物(09926.HK)发布自愿公告,公司自主研发的全球首创PD-1/VEGF双特异性抗体依达方(依沃西)单药对比帕博利珠单药用于一线治疗PD-L1表达阳性(TPS≥1%)局部晚期或转移性非小细胞肺癌(NSCLC)的III期临床研究AK112-303/HARMONi-2,经独立数据监察委员会(IDMC)评估的预先设定总生存期(OS)期中分析结果显示:研究达到OS关键次要终点,取得具有统计学显著和临床获益的阳性结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033863199059.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033863199059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348827113.USD","LU0348825331.USD","LU2476274308.USD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0348783233.USD","LU2399975544.HKD","LU0348735423.USD","BK1161","LU2778985437.USD","BK1574","LU0417516738.SGD","LU1720050803.USD","KURE","LU0417516571.SGD","LU0561508036.HKD","LU0540923850.HKD","LU1961090484.USD","LU2476274720.SGD","LU1794554557.SGD","LU0348766576.USD","IE00B543WZ88.USD","LU0348767384.USD","LU2488822045.USD","LU0634319403.HKD","09926","LU0348784397.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810334","title":"首個國產IL-17A/F雙靶點抑制劑獲批,這一40年來「有研究無產品」的靶點迎臨床突破|掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810334","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664810334?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 22:37","pubTimestamp":1788359868,"startTime":"0","endTime":"0","summary":"半月临床试验动向根据医药魔方提供的数据,8月15日至8月28日,国家药品监督管理局药品审评中心(CDE)共披露195条创新药临床试验登记信息,其中53条为Ⅱ期及以上的关键临床试验。8月15日至8月28日,国家药品监督管理局批准8款创新药上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023863103683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023863103683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","MEDX","159992","BK1161","IBBQ","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664292817","title":"康寧傑瑞製藥-B(09966.HK)9月2日耗資98.58萬港元回購11.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664292817","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664292817?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 22:27","pubTimestamp":1788359269,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664122038","title":"美股異動 | 再鼎醫藥漲逾7%,DLL3 ADC啓動一線SCLC全球三期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664122038","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664122038?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 21:58","pubTimestamp":1788357538,"startTime":"0","endTime":"0","summary":"消息面上,8月31日,$再鼎医药$在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者,预计2030年6月初步完成。ZL-1310为一款靶向DLL3的ADC新药,采用宜联新一代ADC技术TMALIN构建,以TOPO1抑制剂作为payload,具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491227.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药DLL3 ADC启动一线SCLC全球三期临床","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK4585","BK1588","BK1161","BK4526","BK4139","09688","BK4548","LU2488822045.USD","ZLAB","BK4588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664120338","title":"國家醫保局:不要將病種支付標準與醫務人員績效工資掛鈎;2連板小方製藥披露股價異動公告丨醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2664120338","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664120338?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 21:52","pubTimestamp":1788357123,"startTime":"0","endTime":"0","summary":"丨2026年9月3日星期四丨NO.1国家医保局:不要将病种支付标准与医务人员绩效工资挂钩9月2日上午,国家医保局召开新闻发布会,发布按病种付费3.0版分组方案和技术规范。国家医保局有关负责人强调,病种支付标准是医保部门根据客观发生的历史费用、基于患者群体数据形成的费用“均值”,支付方式改革不是医保的“控费”手段和目的,也不可能要求每一个病例都不超过支付标准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023863049079.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023863049079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","09939","BK1574","603207","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817023","title":"和鉑醫藥:披露戎一平辭任具體緣由","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817023","media":"GPLP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664817023?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 21:41","pubTimestamp":1788356460,"startTime":"0","endTime":"0","summary":"9月2日,和铂医药发布补充公告,对8月27日披露的董事及授权代表人事变动作出进一步说明。公告明确,戎一平博士辞任执行董事,是希望投入更多时间精力处理自身其他商业事务。回顾此前公告,相关人事变动8月27日生效:戎一平博士辞任执行董事,同时不再担任港交所上市规则3.05条项下授权代表;陈侑晨、刘毅获委任为执行董事,陈侑晨接替出任授权代表。戎一平此前确认,其与董事会不存在意见分歧,无其他事项提请股东及港交所关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-02/doc-iniqnaws2682986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814277","title":"康諾亞-B(02162)就司普奇拜單抗注射液東南亞和中亞等18個國家和地區上市註冊和商業化達成許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814277","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814277?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 21:06","pubTimestamp":1788354394,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康诺亚-B 发布公告,康诺亚与跨国医药公司Aeira Pte. Ltd.签署独家许可协议。双方将就康诺亚自主研发的靶向IL-4Rα的单克隆抗体——司普奇拜单抗注射液在东南亚和中亚地区的上市注册和商业化展开合作。根据协议,康诺亚将获得首付款以及不同国家上市申请获批的里程碑付款及商业化里程碑付款,并有权利收取基于许可区域产品净销售额计算高达高双位数率的特许权使用费。康诺亚将持续为Aeira负责司普奇拜单抗注射液的生产和产品供应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02162","IPOS","BK1161","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664081495","title":"創新藥半年報冰火兩重天:百濟神州一款藥賣了161億元、六成藥企還在求生 ,「賣藥」仍是終極命題","url":"https://stock-news.laohu8.com/highlight/detail?id=2664081495","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664081495?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:48","pubTimestamp":1788353325,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官,中国创新药产业交出了一份分水岭式的答卷。行业正在告别烧钱讲故事的阶段,走向赚钱才是硬道理的价值兑现期。这种转变并非行业普涨,而是由商业化放量、出海授权爆发、资金来源多元化三重动力共同推动的分化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862982990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862982990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1719994722.HKD","LU1770034418.SGD","BK1574","MEDX","06160","LU0307460666.USD","BK1161","BK4588","LU1969619763.USD","LU0588546209.SGD","LU0828237510.HKD","BK4139","IBBQ","BK4526","LU0228659784.USD","06978","LNGR","159992","BK1588","LU1303224171.USD","688235","KURE","BK0239","BK4585","BK1500","LU2328871848.SGD","ONC","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814735","title":"康希諾生物上半年海外收入按年增長4724.19% 體系化「出海」打開增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814735","media":"证券日报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814735?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:31","pubTimestamp":1788352260,"startTime":"0","endTime":"0","summary":"上半年公司实现营业收入5.5亿元,同比增长43.81%;归母净亏损同比大幅收窄。最亮眼的变化来自国际化业务:海外收入1.52亿元,同比增长4724.19%。第二条路,也是本次收入爆发的核心推手:技术与产业化能力“出海”。康希诺生物跑出一套复合模式:成品疫苗销售、疫苗中间品供应、工艺技术转移、海外联合临床开发四线并行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-02/doc-iniqmwqs1387320.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-02/doc-iniqmwqs1387320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1515","BK1191","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811365","title":"歐康維視生物-B(01477):OT-211 III期臨床試驗完成患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811365","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811365?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:14","pubTimestamp":1788351299,"startTime":"0","endTime":"0","summary":"欧康维视生物-B公布,OT-211在中华人民共和国开展的III期临床试验已于近日完成合共398名患者的入组。2026年3月,OT-211于中国的III期临床试验完成首例患者入组,标志着 OT-211在中国的临床开发取得重要里程碑进展,并体现了本集团致力于为DED患者推进创新疗法。OT-211已于2025年5月28日获FDA批准用于治疗DED的体征及症状。本次OT-211的成功入组标志着公司与Alcon集团在新药开发领域也形成了强有力的合作与绑定,为后续新药共同探索与开发打下基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BK1574","BMED","PSYK","IBBJ","IBBQ","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819216","title":"榮昌生物(09995):截至8月末累計回購4.1萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819216","media":"智通财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819216?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:01","pubTimestamp":1788350479,"startTime":"0","endTime":"0","summary":"智通财经APP讯,荣昌生物(09995)发布公告,截至2026年8月31日,公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份4.1万股,占公司总股本的比例为0.0073%,回购成交的最高价为109.99元/股,最低价为108.30元/股,支付的资金总额为人民币447.67万元(不含交易佣金等交易费用)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1147","02827","LU1064131003.USD","03130","07233","LU2488822045.USD","03188","LU1064130708.USD","399300","82846","BK0239","159982","LU2328871848.SGD","BK1161","02846","BK1583","LU1969619763.USD","83130","LU2148510915.USD","688331","83188","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新藥:已提交自研創新藥HX9428臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819950?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日,海西新药(02637)发布公告,公司自主研发的创新药项目HXP056之候选药物分子HX9428,已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物,拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","PSYK","BK1161","IBBJ","IBBQ","BMED","BK1574","MDTX","LNGR","159992","MEDX","06978","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819359","title":"執行董事王玉曉減持榮昌生物(09995)1.35萬股 每股作價約81.54港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819359","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819359?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:38","pubTimestamp":1788349091,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,8月27日,执行董事王玉晓减持荣昌生物(09995)1.35万股,每股作价81.5352港元,总金额约为110.07万港元。减持后最新持股数目为2227.86万股,最新持股比例为10.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","LU1064130708.USD","BK1583","EWH","LU2328871848.SGD","BK0239","LU1064131003.USD","LU1969619763.USD","688331","LU2148510915.USD","LU2488822045.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811819","title":"深入挖掘創新項目 深圳市市場監督管理局組織開展2026年醫療器械重點創新項目路演遴選活動","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811819","media":"深圳新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811819?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:25","pubTimestamp":1788348300,"startTime":"0","endTime":"0","summary":"深圳市市场监督管理局已连续两年开展医疗器械重点创新项目路演遴选活动。2026年深圳市市场监督管理局将延续去年经验做法,为遴选出的项目提供快速链接服务,助力项目加快注册审批、实现成果转化。下一步,深圳市市场监督管理局将根据本次路演遴选结果,向国家药监局、省药监局及产业部门精准推荐重点服务项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-02/doc-iniqmwqu2753585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IEIH","MDEV","AGNG","MEDX","BK1574","09996","BK1100","BK1583","PTH","GDOC","RSPH","HART","LGHT","159883","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664546816","title":"東方證券股份有限公司(DFZQ)減持康諾亞-B(02162.HK)4.8萬股 每股作價78.401港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664546816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664546816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:19","pubTimestamp":1788347999,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1564","BK1147","BK1583","BK1587","03958","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":16,"totalSize":348,"code":"91000000","status":"200"}]}}